For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

Other

Glutathione Dosage, Protocol & Research Guide

By Sam, MBALast reviewed October 2026

  • MW 307.33 g/mol
  • CAS 70-18-8
Dosage, protocol, reconstitution and storage reference for Glutathione, with a reconstitution calculator, vial sizes and cited research.

Dose overview

Every range below is taken from the cited source and carries its evidence grade.

Human data and community reports

Human data and community reports
SourcePopulationDoseFrequencyRouteDurationEvidence
Mov Disord 2009 (doi 10.1002/mds.22401), randomized, double-blind, placebo-controlled pilot[1]humanadults with Parkinson's disease (n = 21)1,400 mg[1]intravenousthree times a week for 4 weeksintravenous— Human clinical trialStudy details from the source: Mov Disord 2009 (doi 10.1002/mds.22401), randomized, double-blind, placebo-controlled pilot: intravenous glutathione 1,400 mg three times a week for 4 weeks in adults with Parkinson's disease; well tolerated, adverse events similar to placebo, no significant difference in UPDRS scores
Eur J Nutr 2015 (doi 10.1007/s00394-014-0706-z), 6-month randomized, double-blinded, placebo-controlled trial[2]humanhealthy non-smoking adults (n = 54)250–1,000 mg[2]oral, two dose groups: 250 mg/day and 1,000 mg/daydaily for 6 monthsoral— Human clinical trialStudy details from the source: Eur J Nutr 2015 (doi 10.1007/s00394-014-0706-z), 6-month randomized, double-blinded, placebo-controlled trial: oral glutathione 250 or 1,000 mg/day raised glutathione in blood, erythrocytes, plasma and lymphocytes; levels returned to baseline after a 1-month washout
2012 study (doi 10.3109/09546631003801619), randomized, double-blind, placebo-controlled[3]humanhealthy medical students (n = 60)500 mg[3]oraldaily in two divided doses for 4 weeksoral— Human clinical trialStudy details from the source: 2012 study (doi 10.3109/09546631003801619), randomized, double-blind, placebo-controlled: oral glutathione 500 mg/day in two divided doses for 4 weeks; very well tolerated; melanin index fell more than with placebo at two of six sites

Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.

Reconstitution calculator

Sizes in published sources600 mg1500 mg

Calculator example, not a recommended amount

Concentration
300 mg/mL
Volume to draw
0.0008 mL
Units on a U-100 syringe
0.1 units

0102030405060708090100

Properties

CAS
70-18-8
Molecular weight
307.33 g/mol
Formula
Not yet recorded
Sequence
Not yet recorded
Aliases
GSH, L-Glutathione (reduced)
Vial sizes (mg)
600, 1500

Storage notes

Lyophilized
Not yet recorded from a cited source
Reconstituted stability (days)
Not yet recorded from a cited source

Side effects, contraindications and regulatory status

Reported side effects

  • In a 4-week trial of intravenous glutathione 1,400 mg three times a week (21 adults with Parkinson's disease), adverse events were similar to placebo and none led to withdrawal.[1] Human trial
  • Oral glutathione 500 mg/day for 4 weeks (60 healthy adults) was very well tolerated; the authors state that long-term safety has not been established.[3] Human trial

Report any adverse reaction to a qualified healthcare professional.

What the research says

Summaries of the cited studies, each with its evidence grade.

  • Mov Disord 2009 (doi 10.1002/mds.22401), randomized, double-blind, placebo-controlled pilot[1]

    Human trial human

    Mov Disord 2009 (doi 10.1002/mds.22401), randomized, double-blind, placebo-controlled pilot: intravenous glutathione 1,400 mg three times a week for 4 weeks in adults with Parkinson's disease; well tolerated, adverse events similar to placebo, no significant difference in UPDRS scores

    Human clinical trial

  • Eur J Nutr 2015 (doi 10.1007/s00394-014-0706-z), 6-month randomized, double-blinded, placebo-controlled trial[2]

    Human trial human

    Eur J Nutr 2015 (doi 10.1007/s00394-014-0706-z), 6-month randomized, double-blinded, placebo-controlled trial: oral glutathione 250 or 1,000 mg/day raised glutathione in blood, erythrocytes, plasma and lymphocytes; levels returned to baseline after a 1-month washout

    Human clinical trial

  • 2012 study (doi 10.3109/09546631003801619), randomized, double-blind, placebo-controlled[3]

    Human trial human

    2012 study (doi 10.3109/09546631003801619), randomized, double-blind, placebo-controlled: oral glutathione 500 mg/day in two divided doses for 4 weeks; very well tolerated; melanin index fell more than with placebo at two of six sites

    Human clinical trial

Frequently asked questions

What dose figures are published for Glutathione?

Cited figures on this page: 1400 mg three times a week for 4 weeks, intravenous [1] (Human clinical trial, evidence grade B); 250-1000 mg daily for 6 months, oral, two dose groups: 250 mg/day and 1,000 mg/day [2] (Human clinical trial, evidence grade B); 500 mg daily in two divided doses for 4 weeks, oral [3] (Human clinical trial, evidence grade B). These are summaries of published sources, not medical advice. Each figure links to its source in the references.

Compound facts

Recorded molecular weight: 307.33 g/mol.
Recorded CAS number: 70-18-8
Not yet recorded from a cited source.

Sources

https://pubchem.ncbi.nlm.nih.gov/compound/124886
PubMed IDs
19230029, 24791752, 20524875

References

Numbered sources used on this page. Markers in the text link here.

  1. Mov Disord 2009 (doi 10.1002/mds.22401), randomized, double-blind, placebo-controlled pilot pubmed.ncbi.nlm.nih.gov Human trial
  2. Eur J Nutr 2015 (doi 10.1007/s00394-014-0706-z), 6-month randomized, double-blinded, placebo-controlled trial pubmed.ncbi.nlm.nih.gov Human trial
  3. 2012 study (doi 10.3109/09546631003801619), randomized, double-blind, placebo-controlled pubmed.ncbi.nlm.nih.gov Human trial